(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 27.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Karyopharm Therapeutics's revenue in 2026 is $146,067,000.On average, 9 Wall Street analysts forecast KPTI's revenue for 2026 to be $2,598,789,947, with the lowest KPTI revenue forecast at $2,358,667,405, and the highest KPTI revenue forecast at $3,039,228,618. On average, 8 Wall Street analysts forecast KPTI's revenue for 2027 to be $3,810,409,033, with the lowest KPTI revenue forecast at $2,389,118,392, and the highest KPTI revenue forecast at $6,685,642,577.
In 2028, KPTI is forecast to generate $5,675,073,380 in revenue, with the lowest revenue forecast at $2,414,249,628 and the highest revenue forecast at $10,317,748,241.